In the Phase 2 open-label Oral Anaphylm Symptom Intervention Study ("OASIS”) study, adults with Oral Allergy Syndrome (n=36) received Anaphylm under different conditions, including single and repeat ...
AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...
ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years and older. One capsule of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback